Wedbush Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective hoisted by investment analysts at Wedbush from $55.00 to $80.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target indicates a potential upside of 0.97% from the company’s current price.

DNTH has been the topic of a number of other reports. Robert W. Baird raised their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Monday. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research report on Monday. Oppenheimer raised their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday. Finally, HC Wainwright increased their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $115.33.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $79.23 on Tuesday. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $84.86. The firm’s 50-day simple moving average is $49.17 and its 200-day simple moving average is $41.17. The firm has a market cap of $3.42 billion, a P/E ratio of -22.77 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Fairmount Funds Management LLC increased its position in Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after buying an additional 600,000 shares during the period. Vestal Point Capital LP increased its stake in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares during the period. Wellington Management Group LLP raised its holdings in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after buying an additional 2,503,311 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares during the period. Finally, TCG Crossover Management LLC grew its stake in shares of Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision for the Phase 3 CAPTIVATE CIDP trial — the company reported it met the Part A responder criteria (20 confirmed responders with fewer than 40 completers) and will keep the 300mg S.C. dose while engaging regulators to remove the 600mg dose, accelerating the program toward the planned next steps. Early GO Decision Press Release
• Positive Sentiment: Multiple analyst upgrades and higher price targets have lifted sentiment and helped push DNTH to a new 12‑month high; this analyst momentum supports further upside expectations. Analyst Upgrade / 12-Month High
• Neutral Sentiment: Company hosted / scheduled a conference call and webcast to discuss the interim responder analysis (transcript and slides available) — useful for investors seeking detail on responder definitions and next steps but not new data beyond the GO decision. Conference Call / Webcast Notice
• Neutral Sentiment: Short interest data reported appears negligible/zero and does not presently signal a material short pressure or squeeze dynamic. (Entry data showed 0 shares short, 0.0 days to cover.)
• Negative Sentiment: Proposed $400 million underwritten public offering — the company announced a sizable equity raise (with a 30‑day option to upsize by $60M), which can be dilutive and likely caps near‑term upside until proceeds are deployed. Public Offering Announcement
• Negative Sentiment: Q4 earnings miss — DNTH reported a larger-than-expected GAAP loss (EPS -$1.43 vs. consensus -$0.97); while revenue beat nominally, the wider loss underscores current cash burn and execution risks. Q4 Results / Earnings Miss
• Negative Sentiment: New AI/cyber/privacy risk disclosure — the company flagged heightened cyber, privacy and reputational risks related to AI integration, a cautionary corporate‑governance/regulatory risk that could increase compliance costs or negative headlines. AI / Cyber Risk Disclosure

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.